NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nurix Therapeutics, Inc. (NRIX) Stock Analysis

Nurix Therapeutics, Inc. (NRIX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NRIX

$26.14

+$0.82 (+3.24%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NRIX with… →

NRIX Key Statistics

As of Sep 4, 2026
Trading
Open
$25.19
Previous Close
$25.32
Day's Range
24.97–26.22
52-Week Range
8.20–28.23
Volume
1.23M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$2.71B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
73.79
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.58
Financials (FY)
Revenue (FY)
$83.98M+53.95%
Net Income (FY)
−$264.46M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.78M
1-Year Return
+186.62%
Dividend and dates
Earnings Date
October 8, 2026estimated
Avg Volume
2.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NRIX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.80%
2025+0.69%
2024+82.56%
2023−6.01%
2022−62.07%
2021−11.95%
2020 (partial year)+72.96%

As of September 4, 2026.

NRIX Revenue and Earnings by Fiscal Year

FY ends November
Fiscal yearRevenueNet incomeNet margin
2025$83.98M−$264.46M−314.9%
2024$54.55M−$193.57M−354.9%
2023$76.99M−$143.95M−187.0%
2022$38.63M−$180.36M−466.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$83.98M—−$285.67M−$264.46M−314.9%
2024$54.55M—−$213.03M−$193.57M−354.9%
2023$76.99M—−$155.06M−$143.95M−187.0%
2022$38.63M—−$183.87M−$180.36M−466.9%

Annual figures as reported, in the company's reporting currency. As of November 30, 2025.

NRIX Valuation vs Biotechnology Median

Median of 656 stocks
MetricNRIXBiotechnology medianvs median
P/S ratio73.7915.264.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nurix Therapeutics, Inc. (NRIX) at $2.71B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 317.

NRIX last closed at $26.14 on September 4, 2026. That is +$0.82 (+3.24%) against the previous close. Over the past 52 weeks the price has ranged from $8.20 to $28.23. The latest close sits 218.97% above that 52-week low.

Financial Health

In fiscal 2025, Nurix Therapeutics, Inc. reported revenue of $83.98M. That is +53.95% against the prior fiscal year, when revenue was $54.55M. The same year closed with a net loss of $264.46M. The reported profit margin is 0%. Trailing earnings per share are −3.58.

Across the 4 fiscal years on file, revenue moves from $38.63M in 2022 to $83.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 73.79. On price-to-sales that is 4.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.8. Annualized volatility over the trailing 6 years is 77.05%. Over the trailing twelve months the price has returned +186.62%. Measured over 5 years, that is −4.64% a year compounded.

Growth & Income

The record shows no dividend for NRIX.

Across the complete calendar years on file, 2024 returned +82.56% and 2022 returned −62.07%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +37.80% year to date.

Peer Comparison

Nurix Therapeutics, Inc. (NRIX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nurix Therapeutics, Inc. NRIX $2.71B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nurix Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Visit website →